HERZLIYA, Israel and CALGARY, Alberta, May 27, 2026
Innocan Pharma Corporation has reported strong first-quarter 2026 financial results, highlighting continued momentum across its pharmaceutical, veterinary, and consumer wellness businesses. The company generated US$6.47 million in revenue during Q1 2026, representing a 29.7% sequential increase compared with the fourth quarter of 2025, while maintaining an impressive 91.1% gross margin. Alongside its financial performance, Innocan emphasized significant progress in the development of its proprietary LPT-CBD drug delivery platform, a novel long-acting cannabinoid-based technology being advanced for chronic pain management, epilepsy, and veterinary health applications. The results underscore the company’s strategy of combining commercial revenue generation with innovative biopharmaceutical research aimed at addressing large unmet medical needs.
Strong Financial Performance Supports Long-Term Innovation Strategy
During the three months ended March 31, 2026, Innocan reported consolidated revenues of US$6.465 million, reflecting substantial quarter-over-quarter growth despite ongoing uncertainty across global markets. The company’s gross profit reached US$5.89 million, while gross margins remained exceptionally strong at more than 91%, demonstrating the scalability and profitability of its business model.
Management attributed the strong performance to continued growth within its consumer wellness operations and the success of strategic initiatives focused on operational efficiency, market expansion, and cost optimization. While revenue declined on a year-over-year basis compared with the first quarter of 2025, the significant sequential growth highlights improving commercial momentum and strengthening market demand across key business segments.
The company also reported an operating loss of US$0.786 million, an improvement compared with the previous quarter, reflecting ongoing efforts to balance investment in research and development with disciplined operational management. Company executives noted that strategic adjustments implemented across business units have enhanced efficiency and positioned Innocan for sustainable long-term growth despite challenging economic conditions.
Advertisement
LPT-CBD Platform Advances Novel Non-Opioid Treatment Opportunities
A central focus of Innocan’s growth strategy remains the advancement of its proprietary LPT-CBD (Liposomal Platform Technology-Cannabidiol) drug delivery system. The platform is designed to provide precise dosing and sustained release of cannabidiol for approximately four weeks following a single injection, potentially offering a differentiated non-opioid treatment option for chronic pain and neurological disorders.
The company highlighted ongoing progress toward regulatory development pathways, including previous FDA discussions supporting a potential 505(b)(2) regulatory submission strategy, which may streamline future approval processes. The LPT platform remains under preclinical evaluation for multiple indications, including chronic pain management and epilepsy, where long-acting cannabinoid therapies could provide important therapeutic advantages over existing treatment options.
Innocan believes the platform addresses a substantial global market opportunity spanning human health, animal health, and wellness applications. By combining sustained drug delivery with cannabinoid science, the company aims to develop therapies capable of improving patient adherence, reducing dosing frequency, and enhancing overall treatment outcomes.
The technology continues to generate interest as healthcare providers seek safer alternatives to traditional pain management therapies amid growing concerns regarding opioid dependency and long-term safety risks.
Veterinary Health and Wellness Businesses Drive Diversified Growth
Beyond pharmaceutical development, Innocan continues expanding its presence in veterinary medicine through programs targeting animal pain management. The company reported progress with its veterinary regulatory strategy, including the assignment of a Center for Veterinary Medicine (CVM) Investigational New Animal Drug (INAD) number, an important milestone supporting future development activities in companion animal health.
Management views the veterinary segment as a significant near-term growth opportunity, particularly in the treatment of canine osteoarthritis and chronic pain conditions. These efforts complement the company’s broader strategy of leveraging its proprietary delivery technologies across multiple healthcare sectors.
In addition, Innocan’s consumer wellness division, operated through its majority-owned subsidiary B.I. Sky Global, continues generating meaningful revenue and cash flow. The wellness segment delivered strong commercial performance through advanced online sales channels and maintained high gross margins, providing financial support for ongoing biopharmaceutical research and development investments.
With growing revenue, expanding commercial operations, and continued advancement of its proprietary drug delivery technologies, Innocan Pharma is positioning itself as a diversified healthcare innovator. The combination of strong financial execution, a robust cannabinoid-based pharmaceutical pipeline, veterinary health opportunities, and high-margin wellness operations provides a solid foundation for future growth as the company advances next-generation therapies across multiple healthcare markets.
Source: Innocan Pharma press release
